Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nab-paclitaxel for previously treated advanced soft tissue sarcoma
ChiCTR2100052825Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and paclitaxel in soft tissue sarcoma (STS), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2100052825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052825.